Activity is consistent with routine post-exercise selling to cover taxes or diversify holdings — not an unusual signal. Monitor next 10-Q for any change in revenue trajectory or guidance that could contextualize timing. No immediate read-through for trading strategy.
Price Chart
Executive Summary
Three key insiders at United Therapeutics — including CEO Martine Rothblatt, CFO James Edgemon, and Director Christopher Patusky — collectively sold $2.46 million in open-market transactions over a 7-day period. The sales follow routine derivative exercises, with Patusky accounting for 67% of the total dollar volume. Total open-market proceeds represent just 0.01% of the company's $25.1B market cap.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold $948,381 in open-market transactions across three dates (2026-04-20 to 2026-04-22).
- Director Christopher Patusky sold $1,655,790 in shares on 2026-04-24, following full exercise of options.
- CFO James Edgemon sold $503,649 in shares on 2026-04-20 after exercising 10,000 options.
- All sales were preceded by option exercises; no insider made a net open-market sale without prior exercise.
- Total open-market sale value ($2.46M) represents only 0.01% of UTHR's $25.1B market cap.
Financial Impact
$2.46 million in open-market sales over 7 days (0.01% of market cap)
Risk Factors
- Perception risk if media mischaracterizes the cluster as broad insider pessimism.
- Potential for short-term sentiment pressure despite lack of economic significance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1777062710654 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $500.35 $497.31 | ▼ −0.61% | ▼ −2.72% | $571.38 (+14.20%) |
Sep 11, 2026 21d ago | Insider Cluster | $497.11 $494.63 | ▼ −0.50% | ▼ −0.28% | $571.38 (+14.94%) |
Sep 10, 2026 22d ago | Insider Cluster | $503.86 $497.27 | ▼ −1.31% | ▼ −0.81% | $571.38 (+13.40%) |
Sep 9, 2026 23d ago | Insider Cluster | $506.82 $498.48 | ▼ −1.65% | ▼ −0.99% | $571.38 (+12.74%) |
Sep 4, 2026 28d ago | Insider Cluster | $487.61 $502.70 | ▲ +3.09% | ▲ +4.30% | $571.38 (+17.18%) |
Sep 3, 2026 29d ago | Insider Cluster | $488.16 $497.11 | ▲ +1.83% | ▲ +2.98% | $571.38 (+17.05%) |
Aug 28, 2026 5w ago | Insider Cluster | $515.46 $487.61 | ▼ −5.40% | ▼ −5.51% | $571.38 (+10.85%) |
Aug 27, 2026 5w ago | Insider Cluster | $527.91 $492.02 | ▼ −6.80% | ▼ −6.03% | $571.38 (+8.23%) |
Aug 26, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
Aug 25, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access